18+ · Research use only
Retatrutide 20mg, Philippines
Investigational peptide in Phase 3 trials. Lyophilized powder, stocked in Metro Manila. For laboratory research use only.
What it did in trials
- 28.3% avg weight loss, Phase 3
- Lower HbA1c, Phase 2 trial
- Less liver fat, Phase 2 substudy
- 28.3% average weight loss on the top dose over 80 weeks in TRIUMPH-1, a Phase 3 trial in adults with obesity1
- Lower blood sugar (HbA1c down 2.02 points on the top dose) in a Phase 2 trial in adults with type 2 diabetes2
- Reduced liver fat, 82.4% lower on average on the top dose, in a Phase 2 substudy of adults with fatty liver disease3
- Lower food intake in mice, through the GLP-1 and GIP receptors, in the early laboratory work4
- Higher energy expenditure in mice, through the glucagon receptor, in the same laboratory work4
Choose a pack
Pack price replaces the 10% off. One compound per pack.
Pack price replaces the standing 10% off; they don't stack. One compound per pack.
Check out once for the whole cart. Pay by QR, confirm on WhatsApp.
Add more compounds if you like, then check out once. You pay by QR on your order page and send the screenshot on WhatsApp.
In the Philippines
GCash · Maya · QR Ph bank transfer · InstaPay
From abroad
- International transfer
Wise · International bank transfer · Zelle · Crypto
Payment details are sent in the WhatsApp chat once your order is confirmed.
Order by 12 noon on a weekday for same-day Metro Manila
Includes water, syringes, pads · plain box
60-day money-back guaranteeTerms
Order by 12 noon on a weekday for same-day delivery in Metro Manila
Free courier nationwide · Luzon 1-2 days · Visayas 2-3 days · Mindanao 3-5 days
Everything to reconstitute is included
5 x 3ml water · 50 syringes · 50 pads · plain outer packaging
60-day money-back guarantee
If an accredited independent laboratory reports that this vial is not the compound on the label, we refund what you paid for it. Evidence within 60 calendar days of delivery; you do not send anything back. Terms
Delivery proof
Real orders, really delivered
Metro Manila · Same-day
Shipped 1:57 PM, received 2:33 PM. Same day, 36 minutes.
Metro Manila · Customer reply
"Surprised din po ako. Magoorder ako ulit kapag naubos na." They came back and reordered.
Quezon City · Repeat customer
Delivered 11:34 PM. Three weeks later: "Can I order again." "Primara I can say was the best choice."
Real WhatsApp and courier screenshots. Names, numbers and addresses are blacked out.
Updated 26 October 2026
- Human evidence
- Phase 3
- Manufacturing
- cGMP · ISO 9001 · ISO 13485
- Latest batch report
- RETA-4728-A · Sep 2026
- Storage
- 2 to 8 °C sealed
Retatrutide in the Philippines
Retatrutide is an investigational single peptide with agonist activity at three receptors: GLP-1, GIP and glucagon. Semaglutide acts at GLP-1 alone and tirzepatide at GLP-1 and GIP; the glucagon receptor is what retatrutide adds, and in trial populations it is studied for raised energy expenditure alongside the appetite and glycaemic signalling the other two receptors carry. It is in Phase 3 and approved nowhere. TRIUMPH-1, a phase 3 trial in adults with obesity, or overweight with at least one weight-related condition, without diabetes (Lilly investor release, 2026), reported 28.3% mean weight reduction at 80 weeks on the 12mg arm, rising to 30.3% at 104 weeks in the extension cohort. The trial evidence, with the adverse events beside it, is set out below.
Primara Labs stocks retatrutide as a 20mg lyophilized vial, held in cold storage inside Metro Manila. Because inventory is already in the country there is no international shipping leg, no customs exposure and no multi-week wait. Verified orders placed before noon dispatch the same day across Metro Manila, with courier delivery reaches Luzon in 1 to 2 business days, the Visayas in 2 to 3 and Mindanao in 3 to 5.
Each 20mg vial arrives sealed, as a dry powder. Put it in the fridge at 2 to 8°C, away from light, as soon as it lands. To order, tap the WhatsApp button on this page: the chat opens with the vial and pack size already typed, and the reply confirms stock, the peso total and a delivery slot. Orders confirmed before 12 noon get same-day Metro Manila delivery. For the trial history in one place, read the Retatrutide guide on philippinespeptides.com.
Deeper read: Retatrutide price in the Philippines (2026)
Regulatory status
Retatrutide. FDA Philippines: not established. US FDA: Investigational. Sponsor plans a US Biologics License Application submission in Q1 2027. Checked 23 September 2026.
Sold for laboratory research only, not for human consumption. Primara Labs does not give medical advice or dosing guidance. Regulatory Status Tracker
Laboratory handling
Reconstitution reference
| BAC water added | Resulting concentration | Note |
|---|---|---|
| 1.0 ml | 20 mg/ml | Highest concentration, smallest volumes |
| 2.0 ml | 10 mg/ml | Common reference dilution |
| 3.0 ml | 6.67 mg/ml | Larger volumes, finer graduation |
Reconstitute with bacteriostatic water. Reference values are for laboratory preparation only. Other volumes: reconstitution calculator, prefilled for Retatrutide 20mg.
Handling and storage
Sealed vials
Store sealed lyophilised vials refrigerated at 2 to 8 °C, away from light.
Primara Labs storage instructionAdding diluent
Add the diluent slowly down the inside wall of the vial rather than straight onto the powder.
Mixing
The US prescribing instructions for tesamorelin, a lyophilised peptide medicine, tell users to swirl the vial to mix the powder and liquid, and not to shake it.
Tesamorelin US instructions for use, DailyMed · checked 23 September 2026Appearance
The same instructions say not to use the solution if it is cloudy, discoloured or has particles in it.
Tesamorelin US instructions for use, DailyMed · checked 23 September 2026After the stopper is punctured
CDC guidance, citing USP chapter 797, is that a multi-dose vial once opened is dated and discarded within 28 days unless the manufacturer states another date, and never used past its original expiry.
CDC, Preventing Unsafe Injection Practices · checked 23 September 2026What it did in trials
- 28.3% average weight loss on the top dose over 80 weeks in TRIUMPH-1, a Phase 3 trial in adults with obesity1
- Lower blood sugar (HbA1c down 2.02 points on the top dose) in a Phase 2 trial in adults with type 2 diabetes2
- Reduced liver fat, 82.4% lower on average on the top dose, in a Phase 2 substudy of adults with fatty liver disease3
- Lower food intake in mice, through the GLP-1 and GIP receptors, in the early laboratory work4
- Higher energy expenditure in mice, through the glucagon receptor, in the same laboratory work4
Sources for the trial highlights
- 1.TRIUMPH-1, 2026. Adults with obesity, or overweight with at least one weight-related condition, without diabetes.
- 2.Retatrutide phase 2 in type 2 diabetes (Rosenstock et al.), 2023. Adults with type 2 diabetes, HbA1c 7.0 to 10.5% and BMI 25 to 50.
- 3.Retatrutide phase 2 MASLD substudy (Sanyal et al.), 2024. Adults with obesity and metabolic dysfunction-associated steatotic liver disease, liver fat 10% or more.
- 4.LY3437943 discovery study (Coskun et al.), 2022. Obese mice.
Benefits studied
Body-weight reduction
Phase 3 humanIn TRIUMPH-1, a phase 3 trial in adults with obesity, or overweight with at least one weight-related condition, without diabetes (n=2,339), mean body weight fell 28.3% on the 12 mg arm over 80 weeks, against 2.2% lost on placebo (efficacy estimand).
Eli Lilly topline release, 21 May 2026 · checked 23 September 2026Blood sugar control
Phase 3 humanIn TRIUMPH-2, a phase 3 trial in adults with type 2 diabetes and obesity or overweight lasting 80 weeks, a1C fell 1.4, 1.6 and 1.5 points from a baseline of 7.7% on 4, 9 and 12 mg, against 0.2 on placebo.
Eli Lilly topline release, 23 July 2026 · checked 23 September 2026Body-weight reduction with type 2 diabetes
Phase 3 humanIn TRIUMPH-2, a phase 3 trial in adults with type 2 diabetes and obesity or overweight (n=1,152), mean body weight fell 20.8% on the 12 mg arm over 80 weeks, against 4.0% lost on placebo (efficacy estimand).
Eli Lilly topline release, 23 July 2026 · checked 23 September 2026Body-weight reduction with cardiovascular disease
Phase 3 humanIn TRIUMPH-3, a phase 3 trial in adults with severe obesity (BMI of 35 or more) and established cardiovascular disease, with or without type 2 diabetes (n=1,949), mean body weight fell 22.6% on the 12 mg arm over 80 weeks, against 3.2% lost on placebo (efficacy estimand).
Eli Lilly topline release, 23 July 2026 · checked 23 September 2026Knee osteoarthritis pain
Phase 3 humanIn TRIUMPH-4, a phase 3 trial in adults with obesity or overweight and knee osteoarthritis, without diabetes lasting 68 weeks, WOMAC pain fell 4.5 and 4.4 points from a baseline of 6.0 on 9 and 12 mg, against 2.4 on placebo.
Eli Lilly topline release, 11 December 2025 · checked 23 September 2026
Side effects reported
In TRIUMPH-1, discontinuation because of adverse events was 4.1% on 4 mg, 6.9% on 9 mg and 11.3% on 12 mg, against 4.9% on placebo. The most frequently reported adverse events were nausea in 28.6% on 4 mg, 38.4% on 9 mg and 42.4% on 12 mg against 14.8% on placebo, diarrhoea in 25.2% on 4 mg, 34.1% on 9 mg and 32.0% on 12 mg against 13.5% on placebo, constipation in 23.8% on 4 mg, 25.9% on 9 mg and 26.1% on 12 mg against 10.9% on placebo and vomiting in 10.6% on 4 mg, 22.8% on 9 mg and 25.3% on 12 mg against 4.8% on placebo.
Eli Lilly topline release, 21 May 2026 · checked 23 September 2026In TRIUMPH-4, discontinuation because of adverse events was 12.2% on 9 mg and 18.2% on 12 mg, against 4.0% on placebo. The most frequently reported adverse events were nausea in 38.1% on 9 mg and 43.2% on 12 mg against 10.7% on placebo, diarrhoea in 34.7% on 9 mg and 33.1% on 12 mg against 13.4% on placebo, constipation in 21.8% on 9 mg and 25.0% on 12 mg against 8.7% on placebo and vomiting in 20.4% on 9 mg and 20.9% on 12 mg against 0.0% on placebo.
Eli Lilly topline release, 11 December 2025 · checked 23 September 2026Findings are described as the research reported them, with the level of evidence for each. They are not a claim about any vial sold here, which is supplied for laboratory research use only.
How it works
Retatrutide is a single peptide that activates three receptors: GIP, GLP-1 and glucagon. Lilly describes it as a first-in-class triple hormone receptor agonist.
Targets: GIP, GLP-1 and glucagon receptors
What the research shows
Retatrutide has four completed phase 3 trials, TRIUMPH-1 to TRIUMPH-4, reported by Eli Lilly between December 2025 and July 2026, and a phase 2 trial published in 2023. It is studied for obesity and overweight with a weight-related condition, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnoea, chronic low back pain, cardiovascular and renal outcomes, and fatty liver disease (MASLD). Further phase 3 trials are running, including TRIUMPH-5 against tirzepatide.
Phase 3 · 80 weeks
TRIUMPH-1In TRIUMPH-1, a phase 3 trial of retatrutide in adults with obesity, or overweight with at least one weight-related condition, without diabetes (n=2,339), mean body weight fell 19.0% on 4 mg, 25.9% on 9 mg and 28.3% on 12 mg over 80 weeks, against 2.2% on placebo (efficacy estimand; Eli Lilly topline release, 21 May 2026).
In TRIUMPH-1, discontinuation because of adverse events was 4.1% on 4 mg, 6.9% on 9 mg and 11.3% on 12 mg, against 4.9% on placebo. The most frequently reported adverse events were nausea in 28.6% on 4 mg, 38.4% on 9 mg and 42.4% on 12 mg against 14.8% on placebo, diarrhoea in 25.2% on 4 mg, 34.1% on 9 mg and 32.0% on 12 mg against 13.5% on placebo, constipation in 23.8% on 4 mg, 25.9% on 9 mg and 26.1% on 12 mg against 10.9% on placebo and vomiting in 10.6% on 4 mg, 22.8% on 9 mg and 25.3% on 12 mg against 4.8% on placebo.
Phase 3 · 80 weeks
TRIUMPH-2In TRIUMPH-2, a phase 3 trial of retatrutide in adults with type 2 diabetes and obesity or overweight (n=1,152), mean body weight fell 12.7% on 4 mg, 19.1% on 9 mg and 20.8% on 12 mg over 80 weeks, against 4.0% on placebo (efficacy estimand; Eli Lilly topline release, 23 July 2026).
In TRIUMPH-2, discontinuation because of adverse events was 3.8% on 4 mg, 11.6% on 9 mg and 7.7% on 12 mg, against 4.9% on placebo. The most frequently reported adverse events were diarrhoea in 27.4% on 4 mg, 33.5% on 9 mg and 33.6% on 12 mg against 13.2% on placebo, nausea in 13.7% on 4 mg, 20.8% on 9 mg and 28.0% on 12 mg against 8.0% on placebo, constipation in 14.0% on 4 mg, 16.2% on 9 mg and 16.8% on 12 mg against 9.4% on placebo and decreased appetite in 5.8% on 4 mg, 12.3% on 9 mg and 17.1% on 12 mg against 4.5% on placebo.
Phase 3 · 80 weeks
TRIUMPH-3In TRIUMPH-3, a phase 3 trial of retatrutide in adults with severe obesity (BMI of 35 or more) and established cardiovascular disease, with or without type 2 diabetes (n=1,949), mean body weight fell 21.6% on 9 mg and 22.6% on 12 mg over 80 weeks, against 3.2% on placebo (efficacy estimand; Eli Lilly topline release, 23 July 2026).
In TRIUMPH-3, discontinuation because of adverse events was 9.8% on 9 mg and 13.5% on 12 mg, against 4.8% on placebo. The most frequently reported adverse events were diarrhoea in 30.1% on 9 mg and 24.4% on 12 mg against 8.7% on placebo, nausea in 21.7% on 9 mg and 22.4% on 12 mg against 5.8% on placebo, constipation in 18.0% on 9 mg and 15.7% on 12 mg against 7.1% on placebo and decreased appetite in 13.5% on 9 mg and 14.5% on 12 mg against 3.0% on placebo.
Phase 3 · 68 weeks
TRIUMPH-4In TRIUMPH-4, a phase 3 trial of retatrutide in adults with obesity or overweight and knee osteoarthritis, without diabetes (n=445), mean body weight fell 26.4% on 9 mg and 28.7% on 12 mg over 68 weeks, against 2.1% on placebo (efficacy estimand; Eli Lilly topline release, 11 December 2025).
In TRIUMPH-4, discontinuation because of adverse events was 12.2% on 9 mg and 18.2% on 12 mg, against 4.0% on placebo. The most frequently reported adverse events were nausea in 38.1% on 9 mg and 43.2% on 12 mg against 10.7% on placebo, diarrhoea in 34.7% on 9 mg and 33.1% on 12 mg against 13.4% on placebo, constipation in 21.8% on 9 mg and 25.0% on 12 mg against 8.7% on placebo and vomiting in 20.4% on 9 mg and 20.9% on 12 mg against 0.0% on placebo.
Phase 2 · 48 weeks
Retatrutide phase 2 (Jastreboff)In Retatrutide phase 2 (Jastreboff), a phase 2 trial of retatrutide in adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related condition (n=338), mean body weight fell 8.7% on 1 mg, 17.1% on 4 mg (pooled), 22.8% on 8 mg (pooled) and 24.2% on 12 mg over 48 weeks, against 2.1% on placebo (Jastreboff AM et al. N Engl J Med 2023;389:514-526).
Retatrutide phase 2 (Jastreboff): The abstract reports gastrointestinal events as the most common, dose-related and mostly mild to moderate, without rates; rates by arm are in the full text, not read here.
| Batch | Lab | Test | Result | Analysed | Verify |
|---|---|---|---|---|---|
| RETA-4728-A | Janoshik | Bacterial endotoxin (LAL) | 6.066 EU per vial | 21 September 2026 | Task 234146 Key H2KI86I8GWB4 Verify on Janoshik |
| This report covers bacterial endotoxin only. It does not establish identity or purity. | |||||
Every key is printed as text so it can be checked on the laboratory's own site without going through us. Reading an endotoxin result · All batch reports · Look up the batch printed on a vial
- Type
- Peptide triple hormone receptor agonist
- Presentation
- Lyophilized powder, 20 mg / vial
- Vial size
- 20mg
- Catalogue code
- PRM-019
PubChem holds no compound record under the name retatrutide (checked 23 September 2026), and the originating paper is not open access, so formula, weight, CAS and sequence are not published here.
Frequently asked
Retatrutide questions, answered
How much is Retatrutide in the Philippines?
At Primara Labs, Retatrutide 20mg is ₱3,390 for a single vial, ₱2,643 per vial in a 5 pack (₱13,215 total) and ₱2,076 per vial in a 10 pack (₱20,760 total). Prices are in pesos and the pack price is shown on the product page before you order.
Where can I buy Retatrutide in the Philippines?
Primara Labs keeps Retatrutide 20mg in stock in Metro Manila cold storage. Two ways to order: add to cart and pay by QR (GCash, Maya, QR Ph, InstaPay), or message us on WhatsApp to pay by Wise, international bank transfer, Zelle or crypto.
Do you deliver Retatrutide to Cebu, Davao and the provinces?
Yes. Metro Manila: same day before 12 noon, Grab Express / Lalamove, ₱150; Luzon: 1 to 2 business days, J&T Express, ₱250; Visayas: 2 to 3 business days, J&T Express, ₱250; Mindanao: 3 to 5 business days, J&T Express, ₱300. Cebu is in the Visayas and Davao in Mindanao. Courier is free on orders over ₱10,000 anywhere in the Philippines. Below that, a Metro Manila rider is ₱150, J&T Express is ₱250 to Luzon and the Visayas and ₱300 to Mindanao.
Is Retatrutide FDA approved in the Philippines?
Retatrutide. FDA Philippines: not established. US FDA: Investigational. Sponsor plans a US Biologics License Application submission in Q1 2027. Checked 23 September 2026. Primara Labs supplies it for research use only; it is not for human consumption.
What is retatrutide and what does it cost in the Philippines?
Retatrutide is an investigational peptide acting at the GLP-1, GIP and glucagon receptors, in Phase 3 trials for obesity and approved nowhere. Primara Labs stocks it in Metro Manila as a 20mg vial at ₱3,775, or ₱3,390 with the standing 10% off, with same-day metro delivery. Research use only.
How much weight did participants lose in TRIUMPH-1?
TRIUMPH-1, a phase 3 trial in adults with obesity, or overweight with at least one weight-related condition, without diabetes (n=2,339), is the pivotal obesity study. Over 80 weeks, mean body weight fell 19% at 4mg, 25.9% at 9mg and 28.3% at 12mg, against 2.2% on placebo (efficacy estimand, Lilly topline release, May 2026). In a pre-specified extension of 532 participants with a baseline BMI of 35 or more who completed the 80-week study, the 12mg arm reached 30.3% at 104 weeks.
Is retatrutide in stock and how fast is delivery?
Retatrutide 20mg is in stock. Verified orders placed before noon dispatch the same day across Metro Manila. Provincial orders ship by courier and reach Luzon in 1 to 2 business days, the Visayas in 2 to 3 and Mindanao in 3 to 5.
Is retatrutide legal in the Philippines?
Retatrutide is an investigational compound, not a controlled substance in the Philippines. It is supplied strictly for laboratory research use only and is not FDA approved for human use.
How is retatrutide reconstituted for research use?
The lyophilized powder is reconstituted with bacteriostatic water. Adding 2.0 ml to a 20mg vial yields a 10 mg/ml reference concentration. Reconstituted material should be refrigerated and used within 28 days.
How does local stock change delivery compared to importing?
Ordering from overseas suppliers means customs screening at NAIA, uncontrolled temperatures over a 1 to 3 week transit and no recourse if a package is held. Primara Labs vials are already inside the Philippines, so Metro Manila orders arrive the same day and provincial orders within days.
How do I order retatrutide from Primara Labs?
Two ways to order: add to cart and pay by QR (GCash, Maya, QR Ph, InstaPay), or message us on WhatsApp to pay by Wise, international bank transfer, Zelle or crypto. On WhatsApp, tap the order button on this page and the chat opens with your vial pre-filled; on the cart route, your order page shows the payment QR and you send the screenshot on WhatsApp.
How does Primara's retatrutide price compare per milligram?
A single 20mg vial at ₱3,390 works out at ₱170 per milligram, a 5 pack at ₱132 per milligram and a 10 pack at ₱104 per milligram. At every one of those tiers, the per-milligram price is the lowest in the comparison table on this page, where competitor figures were read on 25 August 2026.
Do you give dosing guidance?
No. Retatrutide is supplied for laboratory research only. Primara Labs does not advise on human dosing, titration or administration, on this page or in chat. The reconstitution reference on this page covers concentration only.
What does the batch number on the vial mean?
Each vial carries the production lot it came from. If you message us with the batch number we can tell you when that lot was received and how it was stored.
Can clinics or resellers buy retatrutide in volume?
Yes. Terms are set per account over WhatsApp rather than published. The wholesale page explains the three programmes.
What is Retatrutide studied for?
Retatrutide has four completed phase 3 trials, TRIUMPH-1 to TRIUMPH-4, reported by Eli Lilly between December 2025 and July 2026, and a phase 2 trial published in 2023. It is studied for obesity and overweight with a weight-related condition, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnoea, chronic low back pain, cardiovascular and renal outcomes, and fatty liver disease (MASLD). Further phase 3 trials are running, including TRIUMPH-5 against tirzepatide.
What side effects were reported for Retatrutide?
In TRIUMPH-1, discontinuation because of adverse events was 4.1% on 4 mg, 6.9% on 9 mg and 11.3% on 12 mg, against 4.9% on placebo. The most frequently reported adverse events were nausea in 28.6% on 4 mg, 38.4% on 9 mg and 42.4% on 12 mg against 14.8% on placebo, diarrhoea in 25.2% on 4 mg, 34.1% on 9 mg and 32.0% on 12 mg against 13.5% on placebo, constipation in 23.8% on 4 mg, 25.9% on 9 mg and 26.1% on 12 mg against 10.9% on placebo and vomiting in 10.6% on 4 mg, 22.8% on 9 mg and 25.3% on 12 mg against 4.8% on placebo. In TRIUMPH-4, discontinuation because of adverse events was 12.2% on 9 mg and 18.2% on 12 mg, against 4.0% on placebo. The most frequently reported adverse events were nausea in 38.1% on 9 mg and 43.2% on 12 mg against 10.7% on placebo, diarrhoea in 34.7% on 9 mg and 33.1% on 12 mg against 13.4% on placebo, constipation in 21.8% on 9 mg and 25.0% on 12 mg against 8.7% on placebo and vomiting in 20.4% on 9 mg and 20.9% on 12 mg against 0.0% on placebo.
How should Retatrutide be stored?
Store sealed lyophilised vials refrigerated at 2 to 8 °C, away from light. CDC guidance, citing USP chapter 797, is that a multi-dose vial once opened is dated and discarded within 28 days unless the manufacturer states another date, and never used past its original expiry.
Does Primara Labs publish lab reports for Retatrutide?
Retatrutide 20mg batch RETA-4728-A is Janoshik-tested for bacterial endotoxin: 6.066 EU per vial, analysed 21 September 2026 (task 234146, key H2KI86I8GWB4). This report covers bacterial endotoxin only. It does not establish identity or purity. Reports covering identity, amount and purity are published at primaralabs.com/coa per batch as they are issued.
Local market, read on 25 August 2026
Retatrutide prices in the Philippines, per milligram
| Seller | Vial | Price | Per mg |
|---|---|---|---|
| Primara Labsthis page | 20mg | ₱3,390 | ₱170 |
| Noxa Labs | 20mg | ₱3,849 | ₱192 |
| Noxa Labs | 10mg | ₱2,999 | ₱300 |
| Baseline Labs | 5mg | ₱2,359 | ₱472 |
Primara Labs stocks retatrutide as a 20mg vial at ₱3,390, ₱170 per milligram. Noxa's 20mg vial is ₱192 per milligram, the next lowest in this table. Beyond the single vial, our pack ladder is cheaper per milligram at every tier and the vial arrives ready to reconstitute.
Competitor figures were read off each seller's own product page on 25 August 2026 and are a dated snapshot. The full retatrutide price comparison carries every pack tier, and the retatrutide price in the Philippines post covers how the market has moved. Stock sits in Metro Manila, so same-day Metro Manila delivery applies to every figure here, and what we do and do not claim sets out the rest. For the research background rather than the price, there is a retatrutide guide for the Philippines on our editorial partner's site.
Related compounds
All compounds supplied by Primara Labs are for laboratory research use only and are not for human consumption, diagnostic or therapeutic use. Statements on this page describe published research and have not been evaluated by the Philippine FDA. See Research Use Only terms.